Abstract
Mdm2 binding protein (MTBP) has been implicated in cell-cycle arrest and the Mdm2/p53 tumor suppressor pathway through its interaction with Mdm2. To determine the function of MTBP in tumorigenesis and its potential role in the Mdm2/p53 pathway, we crossed Mtbp-deficient mice to Eμ-myc transgenic mice, in which overexpression of the oncogene c-Myc induces B-cell lymphomas primarily through inactivation of the Mdm2/p53 pathway. We report that Myc-induced B-cell lymphoma development in Mtbp heterozygous mice was profoundly delayed. Surprisingly, reduced levels of Mtbp did not lead to an increase in B-cell apoptosis or affect Mdm2. Instead, an Mtbp deficiency inhibited Myc-induced proliferation and the upregulation of Myc target genes necessary for cell growth. Consistent with a role in proliferation, Mtbp expression was induced by Myc and other factors that promote cell-cycle progression and was elevated in lymphomas from humans and mice. Therefore, Mtbp functioned independent of Mdm2 and was a limiting factor for the proliferative and transforming functions of Myc. Thus, Mtbp is a previously unrecognized regulator of Myc-induced tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alt JR, Greiner TC, Cleveland JL, Eischen CM . (2003). Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22: 1442–1450.
Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A et al. (2003). Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell 11: 905–914.
Boyd MT, Vlatkovic N, Haines DS . (2000). A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem 275: 31883–31890.
Brady M, Vlatkovic N, Boyd MT . (2005). Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol 25: 545–553.
Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. (2006). High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313–325.
Eischen CM, Alt JR, Wang P . (2004). Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23: 8931–8940.
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL . (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658–2669.
Eischen CM, Woo D, Roussel MF, Cleveland JL . (2001). Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21: 5063–5070.
Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM et al. (2008). Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 27: 1813–1820.
Langdon WY, Harris AW, Cory S, Adams JM . (1986). The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: 11–18.
Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI . (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686–1690.
Marine JC, Lozano G . (2010). Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17: 93–102.
Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC et al. (2007). Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 67: 10736–10743.
Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA et al. (2005). Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7: 433–444.
Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA et al. (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 66: 6598–6605.
Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW . (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670–2677.
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031–1044.
Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM . (2008). Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27: 1590–1598.
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433.
Acknowledgements
We thank Dr Silvia Plaza, Brandon Metge, Jane Kennedy, and Dr Chris Carbone for expert technical assistance, Dr Xavier Graña for assistance with the adenoviruses and the H1299 cell-cycle studies, and Dr William Dupont and Dale Plummer for Kaplan–Meier analysis. We also thank the following individuals for providing recombinant adenoviruses: Dr Joseph Nevins (Duke University) E2F1 and c-Myc, Dr Juan Fueyo (MD Anderson Cancer Center) p16, Dr Wafik El-Deiry (University of Pennsylvania) p21, and Dr Ruiz-Lozano (Burnham Institute) GFP. This work was supported by NCI Grants R01CA098139, R01CA117935 and P30CA068485 (CME); the Leukemia & Lymphoma Society (CME) and P01CA095569 (DH and JG).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Odvody, J., Vincent, T., Arrate, M. et al. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene 29, 3287–3296 (2010). https://doi.org/10.1038/onc.2010.82
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.82